Northwire Canada EditionSunday, July 12, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other

Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24

PRN · Price

Executive Summary

  • Profound Medical announced that first clinical outcomes from the Level 1 post‑market CAPTAIN trial will be presented at the Late‑Breaking and High‑Impact session of the 41st Annual European Association of Urology (EAU 2026) Congress in London on March 13, 2026.
  • The presentation will be delivered by Dr. Laurence Klotz, a leading urologist and investigator on the trial.
  • Profound will issue a detailed press release after the session and host an investor webinar at 11:30 a.m. EDT on March 13 to discuss the data and commercial implications; management will also hold one‑on‑one meetings at the Roth Conference (March 22‑24, 2026).

Key Details

  • CAPTAIN Trial Presentation: Scheduled for March 13, 2026, 9:40 a.m. EDT (1:40 p.m. GMT) during the Late‑Breaking and High‑Impact session at EAU 2026 in London, UK.
  • Presenter: Dr. Laurence Klotz, CM, MD, FRCSC – Professor of Surgery, University of Toronto; Sunnybrook Chair of Prostate Cancer Research; CAPTAIN trial investigator.
  • Investor Webinar: To follow the presentation on March 13 at 11:30 a.m. EDT. Advanced registration required (link provided in release). Dr. Klotz will review CAPTAIN data; Profound management will discuss commercial implications and next steps toward guideline inclusion.
  • Roth Conference Investor Meetings: Management to attend one‑on‑one meetings with investors at the 38th Annual Roth Conference, March 22‑24, 2026 in Dana Point, California. No webcast will be available; interested parties should contact a Roth representative or email [email protected].
  • Company Background (retained for context): Profound Medical is a commercial‑stage medical device company developing AI‑powered, MRI‑guided, incision‑free therapies (TULSA‑PRO® for prostate and Sonalleve® for pain palliation/gynecologic applications). The TULSA Procedure™ is cleared in multiple global markets.

Notable Quotes

  • No direct quotes were included in the release.
Read the original news release →

More from PROFOUND MEDICAL CORP.